Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Is Not Aventis’ “White Knight”; 2004 Will Be A Transition Year

Executive Summary

GlaxoSmithKline will not make a "white knight" bid for Aventis, GSK said during its Feb. 12 year-end earnings presentation

You may also be interested in...



Novartis Misses Out On Another Merger, But Forces Sanofi To Pay More

Novartis will need to start over in its search for a merger partner after bowing out of the bidding process for Aventis

Novartis Misses Out On Another Merger, But Forces Sanofi To Pay More

Novartis will need to start over in its search for a merger partner after bowing out of the bidding process for Aventis

Biovail To Complete Sales Force Reorganization In April, Adds Specialty Reps

Biovail will complete the reorganization of its sales force, including the addition of two specialty forces, in April, Senior VP-Commercial Operations Kris Peterson said

Related Content

UsernamePublicRestriction

Register

PS043343

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel